| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.18 | 0.0005 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0007 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | -0.12 | 0.001 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.003 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | -0.15 | 0.003 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | -0.15 | 0.004 |
| mRNA | BIBW2992 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.004 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.11 | 0.004 |
| mRNA | (5Z)-7-Oxozeaenol | GDSC1000 | pan-cancer | AAC | 0.092 | 0.004 |
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | 0.41 | 0.004 |